Bayer, best known for its Aspirin brand, just reported that Xarelto met its primary MACE endpoint in the COMPASS study 1.5 years early due to evidence of overwhelming efficacy. The trial had been expected to read out in 2018. It was investigating the use of Xarelto on top of Aspirin in Coronary or Peripheral Artery disease (CAD/PAD).
This compares favourably to other AstraZeneca’s Brilinta showed a15% risk reduction in the PEGASYS study; Plavix showed a 19% risk reduction in the CARISMA trial.
Which such strong data, the Xarelto/Aspirin combination has a fair chance to become a new standard of care in the secondary prevention ACS market.